Increasing physical activity levels of heart failure patients
Research type
Research Study
Full title
Development and feasibility testing of a multi-faceted theory-informed behavioural intervention targeting physical activity in adults with heart failure
IRAS ID
300883
Contact name
Leah Avery
Contact email
Sponsor organisation
Teesside University
ISRCTN Number
ISRCTN16231461
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
0 years, 9 months, 2 days
Research summary
Heart failure (HF) is a chronic disease with increasing prevalence that continues put strain on the NHS in terms of resource and cost, with the majority of cost relating to reoccurring hospitalisations. Effective management of HF can be achieved via self-management, including increasing physical activity (PA) levels of HF patients. However, the number of patients who engage in regular physical activity is sub-optimal. As such, there is a need to determine how to optimally engage HF patients in PA. Increased levels of PA can improve quality of life and reduce symptomatic burden, as well as reduce NHS costs. We aim to develop an intervention to increase PA levels of HF patients for delivery by HCPs. A systematic intervention development approach will be undertaken incorporating evidence from systematic reviews and qualitative interviews with HF patients and HCPs to understand their experiences of current service provision (already completed phase one); codesign work to develop an intervention prototype (i.e. patient intervention and training intervention for HCPs) will be undertaken, followed by a feasibility study of the final multifaceted intervention developed. Fidelity of delivery by HCPs will be assessed and qualitative interviews conducted to determine whether the intervention is acceptable by HCPs and patients and feasible to deliver within the current care pathway. We will collect pre and post intervention PA data from HF patients via an activity monitoring device. HCP’s will be eligible for inclusion in the study if they are involved in the HF clinical care pathway and HF patients will be eligible if they are ≥18 years, have a confirmed diagnosis of HF, and have no contraindications to PA. The study will take place across three secondary care sites over a 9-month time period.
REC name
North West - Greater Manchester West Research Ethics Committee
REC reference
21/NW/0276
Date of REC Opinion
22 Oct 2021
REC opinion
Further Information Favourable Opinion